Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients.
- DOI
- 10.3389/fcimb.2021.669623
- Published
- 2021
- Container
- Frontiers in cellular and infection microbiology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fcimb.2021.669623,
title = {Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients.},
author = {Jøntvedt Jørgensen M and Nore KG and Aass HCD and Layre E and Nigou J and Mortensen R and Tasken K and Kvale D and Jenum S and Tonby K and Dyrhol-Riise AM},
year = {2021},
journal = {Frontiers in cellular and infection microbiology},
doi = {10.3389/fcimb.2021.669623},
url = {https://doi.org/10.3389/fcimb.2021.669623}
}RIS
TY - JOUR TI - Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients. AU - Jøntvedt Jørgensen M AU - Nore KG AU - Aass HCD AU - Layre E AU - Nigou J AU - Mortensen R AU - Tasken K AU - Kvale D AU - Jenum S AU - Tonby K AU - Dyrhol-Riise AM PY - 2021 JO - Frontiers in cellular and infection microbiology DO - 10.3389/fcimb.2021.669623 UR - https://doi.org/10.3389/fcimb.2021.669623 ER -
APA
M, J. J., KG, N., HCD, A., E, L., J, N., R, M., K, T., D, K., S, J., K, T., & AM, D. (2021). Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients.. Frontiers in cellular and infection microbiology. https://doi.org/10.3389/fcimb.2021.669623
Source records
- pubmed · retrieved 2026-11-10T10:26:39.428Z